Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma

Journal of Rheumatology

Volumn 27, Issue 8, 2000, Pages 1917-1921

  Nagaoka, T ^a   Sato, S ^a   Hasegawa, M ^a   Ihn, H ^a   Takehara, K ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Interleukin 6; Localized scleroderma; Soluble gp130; Soluble interleukin 6 receptor

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCTION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SCLERODERMA;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; CYTOKINE RECEPTOR GP130; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; SCLERODERMA, LOCALIZED;

EID: 0033848025     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Serologic abnormalities and their significance in localized scleroderma
2. When is scleroderma not scleroderma?
3. Antinuclear antibodies in localized scleroderma
4. High titers of antibodies to single-stranded DNA in linear scleroderma
5. Anticentromere antibody in localized scleroderma
6. Linear scleroderma: Clinical spectrum, prognosis, and laboratory abnormalities
7. Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea
8. Antinuclear antibodies in localized scleroderma: Unique staining in chromosome spreads
9. Anti-single-strand DNA antibody and muscle involvement in localized scleroderma
10. Antihistone antibodies in patients with localized scleroderma
11. Antigen specificity of antihistone antibodies in localized scleroderma
12. Interleukin-6: An overview
13. Interleukin-6 in biology and medicine
14. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6
15. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma
16. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble sgp130 in patients with systemic sclerosis
17. Interleukin-6 family of cytokine and gp130
18. gp130 and the interleukin-6 family of cytokines
19. Soluble cytokine receptors: Their roles in immunoregulation, disease, and therapy
20. Soluble cytokine receptors
21. Soluble interleukin-6 receptor in biological fluids from human origin
22. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection
23. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy
24. Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases
25. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies
26. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130
27. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: Effects on soluble IL6 receptor and soluble gp130
28. The immune-inflammatory pathophysiology of fibromyalgia: Increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines
29. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma
30. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
31. Antihistone antibodies in systemic sclerosis: Association with pulmonary fibrosis
32. Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma
33. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma
34. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis
35. Soluble CD4 and CD8 in serum from patients with localized scleroderma
36. Elevated soluble CD23 levels in the sera from patients with localized scleroderma